ASH1L and autism: Chemogenetic inhibition of PFC is sufficient to ameliorate autism-like social deficits and abolish absence-like seizures in Ash1l+/GT mice, which reveal potential therapeutic strategies for the treatment of ASH1L-associated ASD and epilepsy.